201. R1128 substances, novel non-steroidal estrogen-receptor antagonists produced by a Streptomyces. III. Pharmacological properties and antitumor activities
- Author
-
Masanobu Kohsaka, Yukiko Abe, Makoto Nishimura, Toshio Goto, Yasuhiro Hori, and Masakuni Okuhara
- Subjects
Male ,medicine.medical_specialty ,Mice, Nude ,Anthraquinones ,Mice, Inbred Strains ,Biology ,Pharmacology ,In Vitro Techniques ,Estrogen Receptor Antagonists ,Rats, Sprague-Dawley ,Mice ,In vivo ,Internal medicine ,Drug Discovery ,medicine ,Androgen Receptor Antagonists ,Animals ,Humans ,Estrogen binding ,Receptor ,IC50 ,Antibiotics, Antineoplastic ,Biological activity ,Antiestrogen ,In vitro ,Rats ,Mice, Inbred C57BL ,Endocrinology ,Receptors, Estrogen ,Mice, Inbred DBA ,Female ,Drug Screening Assays, Antitumor ,Neoplasm Transplantation - Abstract
R1128 B (1,3,6-trihydroxy-8-n-butylanthraquinone), a new antibiotic produced by Streptomyces sp. No. 1128, inhibited estrogen binding to its receptor. The IC50 value of R1128 B for partially purified rat uterine cytosol receptor was 1.2 x 10(-7) M. However, the IC50 value of R1128 B against androgen-receptor binding was about 50-fold greater than that against estrogen-receptor binding. R1128 B was a competitive inhibitor against estrogen-receptor binding. R1128 B inhibited the growth of estrogen-responsive human mammary adenocarcinoma MCF-7 cells in soft agar. This inhibition, however, was reversed when estradiol was added to the culture medium. R1128 B showed antitumor activities against MCF-7 both xenografted to nude mice and implanted in subrenal capsule of mice (SRC assay). The potency of R1128 B was about 8-fold lower than that of tamoxifen both in vitro and in vivo.
- Published
- 1993